Biogen (BIIB) Non-Current Deferred Tax Liability (2016 - 2025)
Biogen has reported Non-Current Deferred Tax Liability over the past 17 years, most recently at $507.6 million for Q4 2025.
- Quarterly results put Non-Current Deferred Tax Liability at $507.6 million for Q4 2025, up 166.46% from a year ago — trailing twelve months through Dec 2025 was $507.6 million (up 166.46% YoY), and the annual figure for FY2025 was $507.6 million, up 166.46%.
- Non-Current Deferred Tax Liability for Q4 2025 was $507.6 million at Biogen, up from $358.1 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for BIIB hit a ceiling of $966.7 million in Q1 2021 and a floor of $118.3 million in Q2 2025.
- Median Non-Current Deferred Tax Liability over the past 5 years was $539.4 million (2022), compared with a mean of $513.7 million.
- Biggest five-year swings in Non-Current Deferred Tax Liability: soared 310.42% in 2024 and later plummeted 79.97% in 2025.
- Biogen's Non-Current Deferred Tax Liability stood at $694.5 million in 2021, then tumbled by 51.81% to $334.7 million in 2022, then skyrocketed by 91.75% to $641.8 million in 2023, then plummeted by 70.32% to $190.5 million in 2024, then soared by 166.46% to $507.6 million in 2025.
- The last three reported values for Non-Current Deferred Tax Liability were $507.6 million (Q4 2025), $358.1 million (Q3 2025), and $118.3 million (Q2 2025) per Business Quant data.